What we're reading, January 22, 2016: the average premium under the Affordable Care Act rose to $408 before tax credits; seniors will face higher Medicare Advantage premiums with a merge between Aetna and Humana; and Hawaii could be the first state to offer long-term care benefits.
Before taking into account tax credits that lower premiums, the average premium under the Affordable Care Act is $408 per month for 2016, which is a 9% increase. However, after tax credits, the average premium enrollees pay is $118, according to The Hill. As the premium level rose, so did the financial assistance from the government, increasing from an average of $268 for 2015 plans to $294 for 2016 plans.
Meanwhile, seniors will face higher Medicare Advantage premiums if Aetna’s proposal to buy Humana is approved by regulators. Reuters reported that Aetna premiums were at least $155 less annually and up to $305 lower annually in counties where it competed with Humana. Aetna has said that beneficiaries who are facing a premium increase in Medicare Advantage could always switch to traditional Medicare.
In Hawaii, seniors could become the first in the country to have access to long-term care benefits. Lawmakers are introducing a bill that would provide seniors with a benefit of $70 per day for 1 year, which could be used to pay family caregivers, hire in-home aids, and help offset the cost of safety equipment, according to The Washington Post. Hawaii would cover the cost of the benefit through a 0.5% increase in the state’s general excise tax.
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
Hospital Participation in Medicare ACOs: No Change in Admission Practices and Spending
August 19th 2025Hospital accountable care organization (ACO) participation did not impact emergency department admission rates, length of stay, or costs, suggesting limited effectiveness in reducing spending for unplanned admissions and challenging hospital-led ACO cost-saving strategies.
Read More
Roflumilast Cream 0.05% Durable, Safe for Younger Pediatric Patients
August 15th 2025The INTEGUMENT-OLE study is an open-label extension analysis that followed a primary investigation from the phase 3 INTEGUMENT-PED trial, which investigated the efficacy and safety of once-daily roflumilast cream 0.05% for atopic dermatitis in children aged 2 to 5 years.
Read More
2 Commerce Drive
Cranbury, NJ 08512